Jinshi Yaoyao: Subsidiary Dexibuprofen Sodium Sustained-Release Tablets are expected to be selected in the twelfth batch of national drug centralized procurement.

Jinshi Pharmaceutical announced that its wholly-owned secondary subsidiary, Zhejiang Deer Pharmaceutical Co., Ltd., participated in the bidding for the twelfth batch of national organized drug centralized procurement. According to the proposed selection results announced by the Joint Procurement Office, Deer Pharmaceutical's diclofenac sodium sustained-release tablets are expected to be selected for this centralized procurement. The estimated sales revenue for this product in the same specification for the 2025 fiscal year is 6.2231 million yuan, accounting for 0.60% of the company's projected revenue for 2025.